These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 36925938)

  • 1. Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease.
    Corbali O; Chitnis T
    Front Neurol; 2023; 14():1137998. PubMed ID: 36925938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
    Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
    Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders.
    Takai Y; Misu T; Fujihara K; Aoki M
    Front Neurol; 2023; 14():1209749. PubMed ID: 37545724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
    Lin L; Wu Y; Hang H; Lu J; Ding Y
    Front Immunol; 2022; 13():853891. PubMed ID: 35898513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review.
    Tanaka K; Kezuka T; Ishikawa H; Tanaka M; Sakimura K; Abe M; Kawamura M
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.
    Höftberger R; Guo Y; Flanagan EP; Lopez-Chiriboga AS; Endmayr V; Hochmeister S; Joldic D; Pittock SJ; Tillema JM; Gorman M; Lassmann H; Lucchinetti CF
    Acta Neuropathol; 2020 May; 139(5):875-892. PubMed ID: 32048003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOG antibody associated disease (MOGAD) presenting with extensive brain stem encephalitis: A case report.
    Olbert E; Brunner C; Alhani N; Našel C; Struhal W
    eNeurologicalSci; 2022 Dec; 29():100432. PubMed ID: 36388768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.
    Sechi E; Cacciaguerra L; Chen JJ; Mariotto S; Fadda G; Dinoto A; Lopez-Chiriboga AS; Pittock SJ; Flanagan EP
    Front Neurol; 2022; 13():885218. PubMed ID: 35785363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
    Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
    Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study.
    Schindler P; Bellmann-Strobl J; Kuhle J; Wildemann B; Jarius S; Paul F; Ruprecht K
    Mult Scler Relat Disord; 2024 Aug; 88():105729. PubMed ID: 38901371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children.
    Horellou P; de Chalus A; Giorgi L; Leroy C; Chrétien P; Hacein-Bey-Abina S; Bourgeois C; Mariette X; Serguera C; Le Grand R; Deiva K
    Front Immunol; 2021; 12():679770. PubMed ID: 34220827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD).
    Li Y; Liu X; Wang J; Pan C; Tang Z
    Front Aging Neurosci; 2022; 14():850743. PubMed ID: 35370624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
    Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
    Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.